Zai Lab Ltd - ESG Rating & Company Profile powered by AI
Complete Sustainability analysis of Zai Lab Ltd are reached by signing in. This page is a zero-cost Environmental, Social and Governance report for Zai Lab Ltd. This Sustainability score for Zai Lab Ltd represents the company's transparency towards the United Nations SDGs.
Zai Lab Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 3.4, social score of 3.4 and governance score of 5.7.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1156 | Vectus Biosystems Ltd | 4.7 | High |
| 1156 | Zynerba Pharmaceuticals Inc | 4.7 | High |
| 1199 | Zai Lab Ltd | 4.6 | High |
| 1199 | Allergan Inc | 4.6 | High |
| 1199 | AroCell AB (publ) | 4.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Zai Lab Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Zai Lab Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Zai Lab Ltd report the average age of the workforce?
Sign up for free to unlockDoes Zai Lab Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Zai Lab Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Zai Lab Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Zai Lab Ltd offer flexible work?
Sign up for free to unlockDoes Zai Lab Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Zai Lab Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Zai Lab Ltd conduct supply chain audits?
Sign up for free to unlockDoes Zai Lab Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Zai Lab Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Zai Lab Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Zai Lab Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Zai Lab Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Zai Lab Ltd disclose water use targets?
Sign up for free to unlockDoes Zai Lab Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Zai Lab Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Zai Lab Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Zai Lab Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Zai Lab Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Zai Lab Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Zai Lab Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Zai Lab Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Zai Lab Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Zai Lab Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Zai Lab Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Zai Lab Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Zai Lab Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Zai Lab Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Zai Lab Ltd disclose its waste policy?
Sign up for free to unlockDoes Zai Lab Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Zai Lab Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Zai Lab Ltd disclose energy use targets?
Sign up for free to unlockDoes Zai Lab Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Zai Lab Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Zai Lab Ltd
These potential risks are based on the size, segment and geographies of the company.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; argenx BV; and Geneseeq Technology Inc. The company was incorporated in 2013 and is headquartered in Shanghai, China.